The combination product market has witnessed significant growth with the recent scientific and technological advancements. Any combination of drugs, devices and biologics are considered combination products, a few examples are inhaler, nasal spray, transdermal system or a drug or biologic with an administration device. The combination product industry is predicted to grow to $186.7 billion by 2027, expanding at a CAGR of 6.4%.
There are numerous benefits of combination products, such as reduction of drug waste, reduced cost of drugs, avoidance of exposure to toxic products when delivered through separated vial and needle, and so on. Companies have now realized the need to define an integrated and cohesive process and adhere to compliance of drug or biologic and device design, development, and manufacturing of their combination products. Hence, industry leaders need to break from the tradition and guide bio-pharma companies to drive comprehensive strategies for combination products.
Click on the "Read More" button to read the entire whitepaper.
Click on the contact icon at the bottom right to talk to our subject matter experts.
